Prospect Capital Corporation Announces Pricing of $167 Million 5.5% Oversubscribed Institutional Unsecured Notes Offering NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) announced today that Prospect priced an institutional offering of approximately $167 million in aggregate principal amount of 5.5% Series A Notes due 2030 (the “Notes”) on October 27, 2025. “We appreciate the strong support and interest we received from over 40 institutional investors for this oversubscribed unsecured bond offering,” said Grier Eliasek,...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Two Directors at Prospect Capital Corp bought 1,295,000 shares at between 2.710USD and 2.722USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...
Prospect Capital Corporation and Affiliate Complete $18 Million Investment in The Ridge NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (“Prospect”) (NASDAQ: PSEC) and an affiliate have provided a first lien senior secured term loan, a first lien senior secured revolving credit facility, and an equity investment to TCSPV Holdings IV, LLC (“The Ridge” or “Company”), aggregating approximately $18 million, in collaboration with Thesis Capital Partners. The Ridge is a physician-led addiction treatment facility that delivers personalized care in a luxurious residenti...
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that , President, CEO and Chairman of the Board and , Chief Financial Officer, will participate in a fireside chat at H.C. Wainwright & Co’s Annual Global Investment Conference on Tuesday, September 9, 2025. Biotech Equity Research Analyst, Emily Bodnar, will moderate the session which is scheduled to begin at 2:30 p.m. ET. To register for and view ...
Prospect Capital Announces Financial Results for June 2025 NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter and fiscal year ended June 30, 2025. FINANCIAL RESULTS All amounts in $000’s exceptper share amounts (on weighted averagebasis for period numbers)Quarter EndedQuarter EndedQuarter EndedJune 30, 2025March 31, 2025June 30, 2024 Net Investment Income (“NII”)$79,043$83,489$102,922NII per Common Share$0.17$0.19$0.25Interest as % of Total Investment Income94....
Prospect Capital Schedules Fiscal Year Earnings Release and Conference Call NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (the “Company” or “Prospect”) today announced it expects to file with the Securities and Exchange Commission its report on Form 10-K containing results for the fiscal year ended June 30, 2024 and to issue its earnings press release on Tuesday, August 26, 2025, after the close of the markets. The Company will host a conference call on Wednesday, August 27, 2025 at 9:00 a.m. Eastern Time. The conference call dial-in number will ...
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. G...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.